Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation

doi:10.3748/wjg.v30.i47.5055

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 47

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (771)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

HTML

540

Figures (1-5)

Tables (1-1)

Sum=691

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=42

Dec 21, 2024 (publication date) through Jan 4, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Dec 21, 2024; 30(47): 5055-5069
Published online Dec 21, 2024. doi: 10.3748/wjg.v30.i47.5055

Table 1 Circulating biochemical levels in metabolic dysfunction-associated fatty liver disease hepatocarcinogenesis

Group	NC	MAFL	MASH	LC	HCC
CPT-II (U/L)	4.69 ± 0.59	3.39 ± 0.48^a	2.57 ± 0.36^b	2.29 ± 0.48^b	2.04 ± 0.29^b
AFP (ng/L)	0.88 ± 0.09	0.96 ± 0.13	1.46 ± 0.39^b	1.62 ± 0.42^b	1.83 ± 0.54^b
GLU (mmol/L)	12.04 ± 3.51	14.84 ± 3.20^a	14.08 ± 3.20	13.21 ± 3.26	13.50 ± 4.93
ALT (IU/L)	14.75 ± 3.02	44.6 ± 14.34^b	62.19 ± 29.79^b	55.55 ± 26.80^b	46.08 ± 13.39^b
AST (IU/L)	15.88 ± 3.29	44.86 ± 9.90^b	44.46 ± 9.25^b	61.99 ± 18.21^b	47.91 ± 21.22^b
Tch (mmol/L)	1.32 ± 0.49	2.72 ± 0.46^b	3.76 ± 0.54^b	3.29 ± 0.24^b	3.50 ± 0.60^b
TG (mmol/L)	0.61 ± 0.19	0.99 ± 0.41^b	1.78 ± 0.25^b	1.81 ± 0.27^b	1.22 ± 0.21^b
HDL (mmol/L)	2.20 ± 0.42	0.67 ± 0.20^b	1.36 ± 0.17^b	1.17 ± 0.13^b	1.47 ± 0.11^b
LDL (mmol/L)	0.38 ± 0.09	1.19 ± 0.40^b	0.65 ± 0.09^b	0.75 ± 0.09^b	0.63 ± 0.05^b
CD44 (μg/L)	6.19 ± 1.88	11.43 ± 3.29^a	16.98 ± 8.28^b	22.63 ± 3.76^b	30.68 ± 7.91^b
CD24 (μg/L)	3.17 ± 0.55	9.83 ± 1.18^b	6.50 ± 2.28^a	9.17 ± 2.86^b	10.50 ± 3.38^b
ALP (U/L)	3.36 ± 2.65	5.89 ± 5.28	9.14 ± 11.1^a	11.02 ± 12.77^b	16.77 ± 13.08^b
GGT (U/L)	17.16 ± 7.67	24.6 ± 9.07^a	38.09 ± 39.35^a	29.82 ± 24.72^a	55.05 ± 30.64^b

^aP < 0.05, compared with the normal control (NC) group.

^bP < 0.01, compared with the NC group.

AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma-glutamyl transferase; GLU: Glucose; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; NC: Normal control; HCC: Hepatocellular carcinoma; MAFL: Metabolic dysfunction-associated fatty liver; MASH: Metabolic dysfunction-associated steato-hepatitis; LC: Liver cirrhosis; Tch: Total cholesterol; TG: Triglyceride; CPT-II: Carnitine palmitoyl transferase-II.

Citation: Wang LL, Lu YM, Wang YH, Wang YF, Fang RF, Sai WL, Yao DF, Yao M. Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation. World J Gastroenterol 2024; 30(47): 5055-5069
URL: https://www.wjgnet.com/1007-9327/full/v30/i47/5055.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i47.5055